[{"id":"88f3eaef-14f2-44c3-90f7-c4ebafee84e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT07474064","created_at":"2026-03-28T01:40:03.816Z","updated_at":"2026-03-28T01:40:03.816Z","phase":"Phase 2","brief_title":"Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC","source_id_and_acronym":"NCT07474064","lead_sponsor":"chenxu","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Aidixi (disitamab vedotin) • Cdactin-O (CBM588)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 146","initiation":"Initiation: 03/26/2026","start_date":" 03/26/2026","primary_txt":" Primary completion: 03/31/2031","primary_completion_date":" 03/31/2031","study_txt":" Completion: 03/31/2035","study_completion_date":" 03/31/2035","last_update_posted":"2026-03-17"},{"id":"778d6e97-aaea-4385-b9ac-14c267296d2e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07474324","created_at":"2026-03-28T01:42:37.705Z","updated_at":"2026-03-28T01:42:37.705Z","phase":"Phase 2","brief_title":"Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial","source_id_and_acronym":"NCT07474324","lead_sponsor":"The First Affiliated Hospital with Nanjing Medical University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e oxaliplatin • Aidixi (disitamab vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 03/15/2026","start_date":" 03/15/2026","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2026-03-16"},{"id":"ec6be1b2-4bb2-4f7d-914f-ec7b055df2df","acronym":"DECIDING","url":"https://clinicaltrials.gov/study/NCT07142200","created_at":"2025-08-30T13:52:10.410Z","updated_at":"2025-08-30T13:52:10.410Z","phase":"Phase 2","brief_title":"A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy as Bladder-preserving Therapy in Patients With Localized HER2-high Expressing Muscle-invasive Bladder Urothelial Carcinoma Following Maximal Transurethral Resection","source_id_and_acronym":"NCT07142200 - DECIDING","lead_sponsor":"RenJi Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aidixi (disitamab vedotin)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-08-26"},{"id":"eebefa81-1645-4e61-b40b-7636aef12cd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT07012031","created_at":"2025-06-14T13:57:15.769Z","updated_at":"2025-06-14T13:57:15.769Z","phase":"Phase 1/2","brief_title":"Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation","source_id_and_acronym":"NCT07012031","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • ERBB3","pipe":" | ","alterations":" HER-2 overexpression","tags":["KRAS • ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki) • Lumakras (sotorasib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 06/06/2025","start_date":" 06/06/2025","primary_txt":" Primary completion: 06/14/2027","primary_completion_date":" 06/14/2027","study_txt":" Completion: 06/14/2027","study_completion_date":" 06/14/2027","last_update_posted":"2025-06-11"},{"id":"251e3807-7c32-48ca-b5d8-dd58192012fb","acronym":"DIVON","url":"https://clinicaltrials.gov/study/NCT06957561","created_at":"2025-09-07T01:29:15.570Z","updated_at":"2025-09-07T01:29:15.570Z","phase":"Phase 1/2","brief_title":"Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer","source_id_and_acronym":"NCT06957561 - DIVON","lead_sponsor":"Sun Yat-sen University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aidixi (disitamab vedotin) • Yidafan (ivonescimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/30/2025","start_date":" 04/30/2025","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2025-05-04"},{"id":"cc900cf1-cbd5-4b72-929f-5a7f0c8da6dd","acronym":"KEYNOTE-797","url":"https://clinicaltrials.gov/study/NCT04042701","created_at":"2021-01-18T19:49:50.989Z","updated_at":"2025-02-25T12:37:23.766Z","phase":"Phase 1","brief_title":"DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04042701 - KEYNOTE-797","lead_sponsor":"Daiichi Sankyo","biomarkers":" EGFR • HER-2 • BRAF • ALK • ROS1","pipe":" | ","alterations":" HER-2 positive • BRAF V600E • EGFR mutation • HR positive • BRAF V600 • HER-2 expression • HER-2 underexpression • ALK mutation • ROS1 fusion","tags":["EGFR • HER-2 • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • BRAF V600E • EGFR mutation • HR positive • BRAF V600 • HER-2 expression • HER-2 underexpression • ALK mutation • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 115","initiation":"Initiation: 02/10/2020","start_date":" 02/10/2020","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2025-02-24"},{"id":"624a9976-a05c-4b20-8113-57cccfb1cb75","acronym":"KEYNOTE-D78","url":"https://clinicaltrials.gov/study/NCT04879329","created_at":"2021-05-10T14:53:12.740Z","updated_at":"2025-02-25T13:53:47.511Z","phase":"Phase 2","brief_title":"A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2","source_id_and_acronym":"NCT04879329 - KEYNOTE-D78","lead_sponsor":"Seagen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Aidixi (disitamab vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 372","initiation":"Initiation: 05/03/2022","start_date":" 05/03/2022","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 05/30/2028","study_completion_date":" 05/30/2028","last_update_posted":"2025-02-20"},{"id":"8d3fc0b2-6af5-4276-b9b3-c9f1505975ad","acronym":"KEYNOTE-D74","url":"https://clinicaltrials.gov/study/NCT05911295","created_at":"2023-06-22T20:09:18.721Z","updated_at":"2025-02-25T13:55:18.081Z","phase":"Phase 3","brief_title":"Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2","source_id_and_acronym":"NCT05911295 - KEYNOTE-D74","lead_sponsor":"Seagen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • Aidixi (disitamab vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 09/22/2023","start_date":" 09/22/2023","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 04/30/2029","study_completion_date":" 04/30/2029","last_update_posted":"2025-02-20"},{"id":"5325032a-dfb5-4381-8e59-f5e1418ec3ae","acronym":"DASH","url":"https://clinicaltrials.gov/study/NCT04704661","created_at":"2021-01-19T20:51:17.334Z","updated_at":"2025-02-25T14:02:10.901Z","phase":"Phase 1","brief_title":"Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial","source_id_and_acronym":"NCT04704661 - DASH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • TP53 • ATM • RAS • CD4","pipe":" | ","alterations":" HER-2 positive • TP53 mutation • HER-2 amplification • HER-2 expression • RAS mutation","tags":["HER-2 • TP53 • ATM • RAS • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • TP53 mutation • HER-2 amplification • HER-2 expression • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki) • ceralasertib (AZD6738)"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 08/09/2021","start_date":" 08/09/2021","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2025-02-19"},{"id":"31764096-6379-4314-a6a8-370698657726","acronym":"","url":"https://clinicaltrials.gov/study/NCT02226276","created_at":"2021-01-18T10:26:21.550Z","updated_at":"2025-02-25T14:14:41.067Z","phase":"","brief_title":"Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer","source_id_and_acronym":"NCT02226276","lead_sponsor":"City of Hope Medical Center","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 positive + HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 positive + HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Kadcyla (ado-trastuzumab emtansine)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 01/07/2015","start_date":" 01/07/2015","primary_txt":" Primary completion: 12/07/2021","primary_completion_date":" 12/07/2021","study_txt":" Completion: 10/30/2025","study_completion_date":" 10/30/2025","last_update_posted":"2025-02-18"},{"id":"7137bb56-9c9c-4ff1-bf66-4a2cdf70604f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04620187","created_at":"2021-01-19T20:34:19.621Z","updated_at":"2025-02-25T14:07:59.706Z","phase":"Phase 2","brief_title":"Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas","source_id_and_acronym":"NCT04620187","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Kadcyla (ado-trastuzumab emtansine)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 12/24/2020","start_date":" 12/24/2020","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2025-02-18"},{"id":"ebc393d7-e583-45ba-8ae9-46feb62c3abf","acronym":"","url":"https://clinicaltrials.gov/study/NCT05376878","created_at":"2022-05-17T12:54:20.623Z","updated_at":"2025-02-25T14:08:52.333Z","phase":"Phase 4","brief_title":"An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis","source_id_and_acronym":"NCT05376878","lead_sponsor":"City of Hope Medical Center","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Trazimera (trastuzumab-qyyp)"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 12/21/2022","start_date":" 12/21/2022","primary_txt":" Primary completion: 02/25/2026","primary_completion_date":" 02/25/2026","study_txt":" Completion: 02/25/2026","study_completion_date":" 02/25/2026","last_update_posted":"2025-02-18"},{"id":"e2a7e1c5-e873-49a1-9d76-b61c5d386ab0","acronym":"DESTINY-Breast07","url":"https://clinicaltrials.gov/study/NCT04538742","created_at":"2021-01-18T21:43:10.527Z","updated_at":"2025-02-25T13:53:25.796Z","phase":"Phase 1/2","brief_title":"A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer","source_id_and_acronym":"NCT04538742 - DESTINY-Breast07","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 positive • HR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • paclitaxel • Perjeta (pertuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Tukysa (tucatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 245","initiation":"Initiation: 12/28/2020","start_date":" 12/28/2020","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2030","study_completion_date":" 01/31/2030","last_update_posted":"2025-02-14"},{"id":"8ec2e9d9-3e26-4f1f-93c7-9dcc604ae768","acronym":"ADAPTHER2-IV","url":"https://clinicaltrials.gov/study/NCT05704829","created_at":"2023-01-30T15:59:31.869Z","updated_at":"2025-02-25T12:29:21.471Z","phase":"Phase 2","brief_title":"NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer","source_id_and_acronym":"NCT05704829 - ADAPTHER2-IV","lead_sponsor":"West German Study Group","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • docetaxel • Perjeta (pertuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Recruiting","enrollment":" Enrollment 402","initiation":"Initiation: 02/05/2024","start_date":" 02/05/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2025-02-11"},{"id":"91d133a9-9ef3-48c9-bf10-dee2c3a46301","acronym":"DO-01","url":"https://clinicaltrials.gov/study/NCT06819007","created_at":"2025-02-25T15:31:02.759Z","updated_at":"2025-02-25T15:31:02.759Z","phase":"Phase 3","brief_title":"Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer","source_id_and_acronym":"NCT06819007 - DO-01","lead_sponsor":"Daiichi Sankyo","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 582","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 11/01/2028","primary_completion_date":" 11/01/2028","study_txt":" Completion: 01/31/2032","study_completion_date":" 01/31/2032","last_update_posted":"2025-02-11"},{"id":"e4341e18-0636-4930-ba0b-0c9da6c26d3f","acronym":"DESTINY-BTC01","url":"https://clinicaltrials.gov/study/NCT06467357","created_at":"2025-02-25T15:45:41.147Z","updated_at":"2025-02-25T15:45:41.147Z","phase":"Phase 3","brief_title":"Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer","source_id_and_acronym":"NCT06467357 - DESTINY-BTC01","lead_sponsor":"AstraZeneca","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Imfinzi (durvalumab) • gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • rilvegostomig (AZD2936)"],"overall_status":"Recruiting","enrollment":" Enrollment 620","initiation":"Initiation: 08/12/2024","start_date":" 08/12/2024","primary_txt":" Primary completion: 06/12/2028","primary_completion_date":" 06/12/2028","study_txt":" Completion: 05/16/2029","study_completion_date":" 05/16/2029","last_update_posted":"2025-02-11"},{"id":"64837254-ecf8-44d3-8267-0595bd882719","acronym":"","url":"https://clinicaltrials.gov/study/NCT05633979","created_at":"2022-12-01T15:57:19.166Z","updated_at":"2025-02-25T15:27:45.382Z","phase":"Phase 1","brief_title":"Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer","source_id_and_acronym":"NCT05633979","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • UGT1A1","pipe":"","alterations":" ","tags":["HER-2 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki) • Ezharmia (valemetostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 02/09/2023","start_date":" 02/09/2023","primary_txt":" Primary completion: 12/31/2030","primary_completion_date":" 12/31/2030","study_txt":" Completion: 12/31/2032","study_completion_date":" 12/31/2032","last_update_posted":"2025-02-10"},{"id":"683158be-dd0a-42cf-9640-03e574df768d","acronym":"SGNDV-005","url":"https://clinicaltrials.gov/study/NCT06003231","created_at":"2023-08-21T14:09:07.249Z","updated_at":"2025-02-25T16:40:09.136Z","phase":"Phase 2","brief_title":"A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2","source_id_and_acronym":"NCT06003231 - SGNDV-005","lead_sponsor":"Seagen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aidixi (disitamab vedotin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 122","initiation":"Initiation: 11/14/2023","start_date":" 11/14/2023","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2028","study_completion_date":" 05/31/2028","last_update_posted":"2025-02-07"},{"id":"95c0229a-8b91-4b07-bbd8-e69278f6a209","acronym":"DESTINY-Gastric03","url":"https://clinicaltrials.gov/study/NCT04379596","created_at":"2021-01-18T21:09:02.628Z","updated_at":"2025-02-25T16:32:08.037Z","phase":"Phase 2","brief_title":"Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)","source_id_and_acronym":"NCT04379596 - DESTINY-Gastric03","lead_sponsor":"AstraZeneca","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • cisplatin • Imfinzi (durvalumab) • 5-fluorouracil • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • oxaliplatin • rilvegostomig (AZD2936) • volrustomig (MEDI5752)"],"overall_status":"Recruiting","enrollment":" Enrollment 413","initiation":"Initiation: 06/03/2020","start_date":" 06/03/2020","primary_txt":" Primary completion: 07/30/2026","primary_completion_date":" 07/30/2026","study_txt":" Completion: 07/30/2026","study_completion_date":" 07/30/2026","last_update_posted":"2025-02-07"},{"id":"b85874df-7e06-4405-a134-b832b090826f","acronym":"RCTS","url":"https://clinicaltrials.gov/study/NCT05586061","created_at":"2022-10-19T13:56:28.812Z","updated_at":"2025-02-25T16:33:09.486Z","phase":"Phase 2","brief_title":"First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer","source_id_and_acronym":"NCT05586061 - RCTS","lead_sponsor":"Qilu Hospital of Shandong University","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • Aidixi (disitamab vedotin) • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 02/10/2023","start_date":" 02/10/2023","primary_txt":" Primary completion: 12/29/2024","primary_completion_date":" 12/29/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-07"},{"id":"583d3d4e-954b-4daf-9f41-90e56eda49dd","acronym":"DYNASTY-Breast02","url":"https://clinicaltrials.gov/study/NCT06018337","created_at":"2023-08-30T14:09:02.590Z","updated_at":"2025-02-25T16:40:10.354Z","phase":"Phase 3","brief_title":"A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)","source_id_and_acronym":"NCT06018337 - DYNASTY-Breast02","lead_sponsor":"DualityBio Inc.","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 expression • HER-2 underexpression • PGR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression • HER-2 underexpression • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • albumin-bound paclitaxel • trastuzumab pamirtecan (BNT323)"],"overall_status":"Recruiting","enrollment":" Enrollment 532","initiation":"Initiation: 01/18/2024","start_date":" 01/18/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2025-02-06"},{"id":"9663b458-bf8e-4744-aded-694ba1c51e6a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06348134","created_at":"2024-04-04T16:39:16.597Z","updated_at":"2025-02-25T13:56:14.439Z","phase":"Phase 2","brief_title":"Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery","source_id_and_acronym":"NCT06348134","lead_sponsor":"University of Chicago","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • letrozole • goserelin acetate • Soltamox (tamoxifen citrate)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 01/01/2026","start_date":" 01/01/2026","primary_txt":" Primary completion: 07/01/2034","primary_completion_date":" 07/01/2034","study_txt":" Completion: 07/01/2036","study_completion_date":" 07/01/2036","last_update_posted":"2025-02-05"},{"id":"bbd54b62-457a-494d-90d2-1614ae83c172","acronym":"DESTINY-Breast08","url":"https://clinicaltrials.gov/study/NCT04556773","created_at":"2021-01-18T21:46:53.987Z","updated_at":"2025-02-25T16:45:09.442Z","phase":"Phase 1","brief_title":"A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT04556773 - DESTINY-Breast08","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 expression • HER-2 underexpression • PGR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • HER-2 underexpression • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • paclitaxel • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • fulvestrant • Truqap (capivasertib) • anastrozole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 138","initiation":"Initiation: 12/17/2020","start_date":" 12/17/2020","primary_txt":" Primary completion: 08/16/2023","primary_completion_date":" 08/16/2023","study_txt":" Completion: 12/04/2025","study_completion_date":" 12/04/2025","last_update_posted":"2025-02-05"},{"id":"c6f6111f-3721-44d3-8d28-6c42b01ad58a","acronym":"DESTINY-Breast11","url":"https://clinicaltrials.gov/study/NCT05113251","created_at":"2021-11-09T12:53:05.265Z","updated_at":"2025-02-25T13:54:06.394Z","phase":"Phase 3","brief_title":"Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer","source_id_and_acronym":"NCT05113251 - DESTINY-Breast11","lead_sponsor":"AstraZeneca","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • Perjeta (pertuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • doxorubicin hydrochloride • cyclophosphamide • Herzuma (trastuzumab-pkrb)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 927","initiation":"Initiation: 10/25/2021","start_date":" 10/25/2021","primary_txt":" Primary completion: 03/12/2025","primary_completion_date":" 03/12/2025","study_txt":" Completion: 04/30/2027","study_completion_date":" 04/30/2027","last_update_posted":"2025-02-05"}]